Table 1
From the following article
RNA interference against viruses: strike and counterstrike
Joost Haasnoot, Ellen M Westerhout & Ben Berkhout
Nature Biotechnology 25, 1435 - 1443 (2007) Published online: 7 December 2007
doi:10.1038/nbt1369
Table 1. Nucleic acid–based antiviral therapeutics that have entered clinical trials
| Virus | Inhibitor (name) | Target gene | Stage | Sponsor | Reference |
|---|---|---|---|---|---|
aChemically synthesized. | |||||
bGene construct. | |||||
cHuman papillomavirus. | |||||
| CMV | Antisense oligonucleotidea (Vitravene; formivirsen/ISIS 2922) | IE2 | Approved | Isis Pharmaceutials (Carlsbad, CA, USA) | 126–128 |
| HIV-1 | Ribozymeb (Rz2, OZ-1) | tat | Phase 1 complete, Phase 2 ongoing | Johnson & Johnson (New Brunswick, NJ, USA) subsidiary Tibotec Therapeutics (Bridgewater, NJ, USA) | 129 |
| Phase 1 complete | Gene Shears and Johnson Research | 130 | |||
| 937-nt antisense geneb (VRX496) | env | Phase 1 complete | VIRxSYS (Gaithersburg, MD, USA) | 131 | |
| Dominant-negative anti-HIV-1 geneb (RevM10) | rev | Phase 1/2 ongoing | Systemix (Palo Alto, CA, USA) and National Cancer Institute (Bethesda, MD, USA) | 132,133 | |
| Phase 1 complete | The Saban Research Institute/USC Keck School of Medicine (Los Angeles) | 134 | |||
| Decoy RNAb | RRE | Phase 1 complete | Childrens Hospital Los Angeles, University of Southern California School of Medicine (Los Angeles, CA) and Baylor College of Medicine (Houston) | 135 | |
| Short-hairpin RNA, ribozyme and RNA decoy b(Triple-R vector) | tat/rev, CCR5, TAR | Phase 1 complete | Colorado State University (Fort Collins, CO, USA) and Beckman Research Institute (Duarte, CA, USA) | 136 | |
| Antisense TAR and RevM10b | TAR, rev | Phase 1 complete | National Human Genome Research Institute (Bethesda, MD, USA) | 137 | |
| Antisense oligonucleotidea (Gem 92) | Gag | Phase 2 discontinued | Hybridon (now Idera Pharmaceuticals, Cambridge, MA, USA) | NA | |
| Antisense (HGTV43)b | ND | Phase 1/2 ongoing | Enzo Biochem (Farmingdale, NY, USA) | NA | |
| Peptide nucleic acid (AVR-118) | ND | Phase 1/2 completed | Advanced Viral Research (Yonkers, NY, USA) | NA | |
| RSV | Small interfering RNAa (ALN-RSV01) | Nucleocapsid | Phase 1 ongoing and phase 2 planned for 2008 | Alnylam Pharmaceuticals (Cambridge, MA, USA) | NA |
| HCV | Ribozyme (Heptazyme)a | IRES | Phase 2 studies discontinued | Ribozyme Pharmaceuticals (Boulder, CO, USA; renamed Sirna, now part of Merck) | 138 |
| Antisense oligonucleotide a(AVI-4065) | ND | Phase 2 studies discontinued | AVI BioPharma (Portland, OR, USA) | NA | |
| Antisense oligonucleotide (ISIS 14803) | IRES | Phase 2 studies discontinued | Isis | NA | |
| Phase 1 completed | Isis | 139 | |||
| HBV | Short-hairpin RNA b (Nuc B1000) | Pre-gen./pre-C, Pre-S1, Pre-S2/S, X | Phase 1 ongoing | Nucleonics (Horsham, PA, USA) | NA |
| HPVc | Antisense oligonucleotidea (MBI 1121) | E1 | Phase 1 discontinued | Migenix (formerly Micrologix Biotech, Vancouver, BC, Canada) | NA |
| Peptide nucleic acid (AVR-118) | ND | Phase 1 discontinued | Advanced Viral Research (Yonkers, NY, USA) | NA | |